Article Text

Download PDFPDF
Prognosis in Patients With Serous and Mucinous Stage I Borderline Ovarian Tumors
  1. Taejong Song, MD*,
  2. Yoo-Young Lee, MD,
  3. Chel Hun Choi, MD,
  4. Tae-Joong Kim, MD,
  5. Jeong-Won Lee, MD, PhD,
  6. Byoung-Gie Kim, MD, PhD and
  7. Duk-Soo Bae, MD, PhD
  1. *Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University; and
  2. Department of Obstetrics& Gynecology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
  1. Address correspondence and reprint requests to Duk-Soo Bae, MD, PhD, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-gu, Seoul, 135-710, Korea. E-mail: dsbae123@skku.edu.

Abstract

Introduction The purpose to this study was to compare the clinicopathologic characteristics and prognosis of patients with serous stage I borderline ovarian tumors (BOTs) to patients with mucinous stage I BOTs.

Methods This was a retrospective cohort series of patients with stage I BOTs diagnosed and treated between 1995 and 2009 at a single institution. The records were analyzed for patients’ clinicopathologic information. The recurrence rates were compared using the Kaplan-Meier method.

Results During the study period, 198 patients (73.6%) with mucinous BOTs and 71 patients (26.4%) with serous BOTs were identified. Patients with serous tumors tended to be asymptomatic (53.5%) and frequently had elevated CA-125 levels and positive results from peritoneal cytology. Conversely, mucinous tumors were more related to the presence of symptoms (70.7%), elevated CA-19-9 levels, and pseudomyxoma and were larger tumors with a mean size of 15.6 cm. After a median follow-up of 56.5 months, 15 patients had developed 16 recurrences. Among these, 14 borderline recurrences developed in 6 patients with mucinous tumors and in 7 patients with serous tumors, and 2 invasive recurrences developed in only patients with mucinous tumors. No difference in recurrence rate between mucinous and serous tumors was observed. In addition, no disease-related death occurred.

Conclusions Our study found that, although distinct differences in clinical and pathologic characteristics between stage I mucinous and serous BOTs are seen, result from tumor histology was not associated with disease prognosis.

  • Borderline ovarian tumor
  • Mucinous tumor
  • Serous tumor

Statistics from Altmetric.com

Footnotes

  • The authors have no conflicts of interest to declare.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.